Facebook
Twitter
LinkedIn
Forward
3rd Annual Wisconsin Primary CNS Malignancy Virtual Symposium
The goal of this educational activity is to present a multi-disciplinary approach to the clinical management of meningioma, discuss available innovative clinical trial options and ideas for future clinical trials, and provide the latest updates on current treatment trends in neurosurgery, radiation oncology, and neuro-oncology. Using a disease-orientated multi-disciplinary approach, along with panel discussions, the activity will provide a comprehensive update for providers from multiple disciplines.
This activity will be virtual only.
Learners will receive a link to the webinar prior to the start of the activity.
Registration Fees:
$50.00 MD/DO
$25.00 RN, APRN, PA, and other healthcare providers
Free: Trainees, including fellows, residents and students
The registration fee includes cost of tuition, and a nonrefundable processing fee of $5.
Target Audience
This activity is designed to educate community general practitioners, oncologists, radiation oncologists, neurosurgeons, advanced practice nurses, PAs, RNs and other healthcare providers on topics relevant to new advances in the diagnosis and treatment of meningiomas.
Learning Objectives
The global learning objectives for this activity are as follows.
By participating in this activity members of the health care team will be able to:
- Describe effective communication and collaboration with partners in care of patients with primary central nervous system lymphoma
- Review updates and best current multidisciplinary treatment strategies for patients with primary central nervous system lymphoma
- Discuss molecular and diagnostic advances in the diagnosis and management of PCNSL
- Identify issues important to patients for overall quality of life
Friday, April 14 All times listed are in Central Daylight Time (CDT) Program may be subject to change. | |
7:45 AM - 8:00 AM | Welcome/Introduction |
Session I | |
8:00 AM - 8:30 AM | Diagnostic Challenges and Molecular Advances in PCNSL Kwun W. Wen, MD, PhD |
| 8:30 AM - 9:00 AM | Neurosurgical Management of PCNSL Mark Kraemer, MD |
| 9:00 AM - 9:30 AM | Advanced Imaging Updates in PCNSL Ramon Barajas, MD |
| 9:30 AM - 10:00 AM | Neurocognitive Function in Patients with PCNSL Denise D. Correa, PhD, ABPP-CN |
| 10:00 AM - 10:15 AM | Panel Discussion |
| 10:15 AM - 10:30 AM | Break |
Session II | |
10:30 AM - 11:00 AM | Updates in the Management of PCNSL—Relapsed/Refractory Disease Ugonma Chukwueke, MD, MPH |
11:00 AM - 11:30 AM | Current Role of Radiation in the Management of PCNSL: How Did We Get Here? Chelsea Pinnix, MD, PhD |
11:30 AM - 12:00 PM | Updates in the Management of PCNSL Andrés JM Ferreri, MD |
| 12:00 PM - 12:30 PM | Noninvasive Risk-Stratification, MRD Monitoring and Disease Classification by Circulating Tumor DNA in CNS Lymphoma Florian Scherer, MD |
| 12:30 PM - 1:00 PM | Panel Discussion |
| 1:00 PM | Adjourn |
This activity will be virtual only via WebEx.
Learners will receive a link to the webinar prior to the start of the activity.
POLICY ON DISCLOSURE
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation.
For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.
| Role | Financial Relationship Disclosures | Discussion of Unlabeled/Unapproved uses of drugs/devices in presentation? |
Mahua Dey, MD | Planning Committee Member/Medical Director
| No relevant relationships with ineligible companies to disclose | No |
Joseph Bovi, MD
| Planning Committee Member | Imaging Biometrics (Independent Contractor - Consultant) | No |
Janelle Poehnelt
| Planning Committee Member | No relevant relationships with ineligible companies to disclose | No |
Jessica Leiberg, DNP
| Planning Committee Member
| No relevant relationships with ineligible companies to disclose | No |
Kimberly Roller Voigt, PA
| Planning Committee Member
| No relevant relationships with ineligible companies to disclose | No |
Ramon Barajas Jr, MD | Faculty | No relevant relationships with ineligible companies to disclose | No |
Ugonma Chukwueke, MD, MPH | Faculty | No relevant relationships with ineligible companies to disclose | Yes |
Denise Correa, PhD, ABPP-CN
| Faculty | No relevant relationships with ineligible companies to disclose | No |
Andres Ferreri, MD
| Faculty | AbbVie (Research Support, Advisory Board), Adienne (Speakers’ Bureau), Amgen (Research Support), ADC Therapeutics (Research Support), Astra Zeneca (Speakers’ Bureau, Advisory Board), BMS (Speakers’ Bureau, Advisory Board), Beigene (Research Support), Genmab (Research Support, Advisory Board), Gilead (Research Support, Speakers’ Bureau, Advisory Board), Hutchinson Med (Research Support), Incyte (Research Support, Advisory Board), Janssen (Research Support), Novartis (Research Support, Speakers’ Bureau, Advisory Board), Pfizer (Research Support), Pharmacyclics (Research Support), PletixaPharm (Research Support, Advisory Board), Roche (Research Support, Consultant, Speakers’ Bureau, Advisory Board), Takeda (Research Support) | Yes |
Mark Kraemer, MD
| Faculty | No relevant relationships with ineligible companies to disclose | No |
Chelsea Pinnix, MD, PhD
| Faculty | American Society for Radiation Oncology (Independent Contractor - Other), Merck (Grant / Contract) | No |
Florian Scherer, MD
| Faculty | Gilead Research Foundation (Grant / Contract), Takeda Oncology (Grant / Contract), ROCHE SEQUENCING SOLUTIONS, INC. (Grant / Contract) | No |
Kwun Wah Wen, MD, PhD
| Faculty | No relevant relationships with ineligible companies to disclose | No |
*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.
 | Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison ICEP and the Medical College of Wisconsin (MCW). The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
American Medical Association (AMA) The University of Wisconsin–Madison ICEP designates this virtual live activity for a maximum of 4.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. American Nurses Credentialing Center (ANCC) The University of Wisconsin–Madison ICEP designates this virtual live activity for a maximum of 4.75 ANCC contact hours. Continuing Education Units (CEUs) The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.475 CEUs or 4.75 hours. | |
 | American Academy of Physician Assistants (AAPA) The University of Wisconsin–Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. |
Available Credit
- 4.75 AAPA Category 1 CME
- 4.75 AMA PRA Category 1 Credit™
- 4.75 ANCC Contact Hours
- 4.75 University of Wisconsin–Madison Continuing Education Hours
- 4.75 Approved for AMA PRA Category 1 Credit™
Price
This activity will be virtual only.
Learners will receive a link to the webinar prior to the start of the activity.
Registration for this activity can only be completed through the ICEP Learning Portal. Attendee registrations made through any other sites cannot be honored. UW-Madison ICEP is not able to refund fees paid through unaffiliated registration sites, such as eMedEvents.com, MedConfWorld.com, EventEgg.com, and 10times.com. Please report any unauthorized websites or solicitations for registrations to info@icep.wisc.edu.
REGISTRATION FEES
$50.00 MD/DO
$25.00 RN, APRN, PA, and other healthcare providers
Free: Trainees, including fellows, residents and students
The registration fee includes cost of tuition, and a nonrefundable processing fee of $5.
COURSE MATERIALS
Course materials will be posted on this site as they become available.
CANCELLATION AND REFUND POLICY
Requests for cancellation must be submitted in writing to help@icep.wisc.edu. Cancellation requests received at least 96 hours prior to the conference will allow a full refund except for the $5 non-refundable processing fee. No refunds will be made for cancellations received less than 96 hours prior to the activity start date.
QUESTIONS ABOUT REGISTRATION
Email help@icep.wisc.edu
PROGRAM CHANGES
Emergency situations occasionally occur and may necessitate topic or speaker changes. The University of Wisconsin–Madison ICEP reserves the right to alter or substitute a topic or speaker without prior notification.
ACCESSIBILITY
The University of Wisconsin provides equal opportunities in employment and programming, including Title IX requirements. The University of Wisconsin fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us at help@icep.wisc.edu
FOR FURTHER INFORMATION
For conference information or details, please contact Janelle Poehnelt, poehnelt@neurosurgery.wisc.edu.
REQUIRED HARDWARE/SOFTWARE
Computer, tablet, or smartphone with audio sharing capabilities.